publication date: Mar. 30, 2017

Multiple Myeloma Carfilzomib produces OS benefit vs. bortezomib in relapsed, refractory disease

Amgen announced positive results from a planned overall survival interim analysis of the Phase III head-to-head ENDEAVOR trial.

The study met the key secondary endpoint of OS, demonstrating that patients with relapsed or refractory multiple myeloma treated with Kyprolis (carfilzomib) and dexamethasone (Kd) lived 7.6 months longer than those treated with Velcade (bortezomib) and dexamethasone (Vd) (median OS 47.6 months for Kd versus 40.0 for Vd, HR=0.79; 95 percent CI: 0.65 – 0.96; p=0.01).

The OS benefit was consistent regardless of prior Velcade therapy (HR 0.75 for no prior Velcade; HR 0.84 for prior Velcade). These data will be presented today during the late-breaking abstract session at the 16th International Myeloma Workshop in New Delhi. 

“Results from the ENDEAVOR primary analysis proved Kyprolis is the superior proteasome inhibitor, having doubled progression-free survival compared to Velcade,” said Meletios Dimopoulos, professor of Clinical Therapeutics at the National and Kapodistrian University of Athens, School of Medicine. “Results presented today showed that progression-free survival advantage translated into significantly improved survival for patients, a clinical endpoint that creates confidence for physicians and patients, especially in a relapsing disease like multiple myeloma.”   

This Kd regimen administered with 56 mg/m2 Kyprolis twice weekly is approved in the U.S., European Union and other countries based on … Continue reading CCL March 2017 – Carfilzomib produces OS benefit vs. bortezomib in relapsed, refractory disease

To access this members-only content, please log in.
If you're not a subscriber why not join today?
If you believe you should be able to view this area but cannot log in, then please contact us and we will try to rectify this issue as soon as possible.
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2017 The Cancer Letter Inc.